Information Provided By: 
Fly News Breaks for March 8, 2016
ACT, CELG
Mar 8, 2016 | 08:23 EDT
After Actavis (AGN) sought permission from the FDA to offer a generic version of Celgene's (CELG) cancer treatment, Abraxane, Wells Fargo does not expect Actavis to be able to offer a generic version of the drug before March 2021. Wells estimates that Abraxane's peak annual EPS contribution to Celgene will be 65c. Wells says that Celgene has many pipeline opportunities, and it keeps an Outperform rating on the shares.
News For CELG;ACT From the Last 2 Days
There are no results for your query CELG;ACT
